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A B S T R A C T
The global introduction of 14 new antiepileptic drugs (AEDs) over the past 20 years as adjunctive
treatment in refractory epilepsy has triggered an increased interest in optimising combination therapy.
With a widening range of available mechanisms of AED action, much activity has been focused on the
deﬁning and reﬁning ‘‘rational polytherapy’’ with AEDs that have differing pharmacological properties.
This paper reviews the available animal and human data exploring this issue. The experimental and
clinical evidence in support of ‘‘rational polytherapy’’ is sparse, with only the combination of sodium
valproate with lamotrigine demonstrating synergism. Robust evidence to guide clinicians on how and
when to combine AEDs is lacking and current practice recommendations are largely empirical. Practical
guidance for the clinician is summarised and discussed in this review. In particular, care should be taken
to avoid excessive drug load, which can be associatedwith decreased tolerability and, therefore, reduced
likelihood of seizure freedom. A palliative strategy should be deﬁned early for the more than 30% of
patients with refractory epilepsy. Nevertheless, the availability of an increasing number of
pharmacologically distinct AEDs has produced a modest improvement in prognosis with combination
therapy, which will encourage the clinician to persevere with continued pharmacological manipulation
when other therapeutic options have been tried or are not appropriate.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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‘‘The combinations of bromide with other drugs are of much
value in the treatment of epilepsy. Inmany cases a greater effect
is produced by the combination than by other drugs given
alone’’ (William Gowers, 1881)
The modern treatment of epilepsy began with potassium
bromide and this drug is still in use to this day.1 The next effective
agent, phenobarbital, was not synthesised until 1911. So what else
was Gowers giving his epilepsy patients together with potassium
bromide? The list included digitalis, belladonna, cannabis, opium,
borax and many other noxious substances. It is well known that
Vincent van Gogh beneﬁted from treatment with potassium
bromide. He also took digitalis for a period of time. Indeed, he may
have been digitoxic when he painted some of the canvases with
bright yellow overtones, since digitalis toxicity traditionally
distorts colour vision in this way. It is unlikely, but not impossible,
that he was taking both drugs together at some point! So if Gowers
had many polytherapy options more than 100 years ago, what* Corresponding author. Tel.: +44 141 211 2534; fax: +44 141 211 2072.
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doi:10.1016/j.seizure.2011.01.004choices does the modern neurologist have in his therapeutic
arsenal for treating drug-resistant epilepsy?
Over the past 20 years, no fewer than 14 antiepileptic drugs
(AEDs) have been licensed for use in the common epilepsies and a
range of more unusual syndromes (Fig. 1). Of these felbamate
(blood dyscrasias and hepatotoxicity) and vigabatrin (concentric
visual ﬁeld defects) are rarely prescribed because of their
association with serious adverse effects.2 Eslicarbazepine is
available in Europe, but not in the United States. Stiripentol has
been licensed for Dravet’s syndrome via the European orphan drug
system3 and ruﬁnamide’s usage is conﬁned to seizures associated
with Lennox–Gastaut syndrome.4 Nevertheless, the potential
choices of AEDs as monotherapy or in combination are so
numerous that it is not possible for a doctor and his or her patient
to try every permutation in a single lifetime. Adding the newer
AEDS to the established drugs brings their total number up to
around 20 for use in the common epilepsies. This allows the
possibility of nearly 200 duotherapies or more than 1000
combinations of 3 AEDs!
Most patients with refractory epilepsy take 2, 3 or even 4 AEDs.
How then are we to rationalise their usage to provide the best
possibility of an optimal outcome? What evidence is there in
support of ‘‘rational polytherapy’’? Conventional wisdom suggests
that combining AEDs with different mechanisms of action is more
likely to produce seizure freedom than prescribing those withvier Ltd. All rights reserved.
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Fig. 1. Chronology of antiepileptic drug introduction over the past 150 years.
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remembered too that the spectrum of efﬁcacy for every drug does
not always correspond to the license.
2. Pharmacological targets
To best use the range of available AEDs, the prescriber must
possess some understanding of what we know about how these
agents act in the brain. The knowledge base regarding their
pharmacology is limited but slowly increasing. We can now
identify a range of mechanisms that differ sufﬁciently from each
other to provide some discrimination in their usage.
Blockade of voltage-gated sodium channels is the most
common mechanism of action among currently available AEDs.5
The established agents phenytoin and carbamazepine are arche-
typal sodium channel blockers,6,7 amechanism they sharewith the
newer drugs lamotrigine, oxcarbazepine, topiramate, felbamate,
zonisamide, ruﬁnamide and lacosamide.8–10 Sodium valproate and
gabapentin may also have inhibitory effects on neuronal sodium
channels.11,12 Voltage-gated sodium channels exist in one of three
basic conformational states; resting, open, and inactivated. During
a single round of depolarisation, channels cycle through these
states in turn and the neurone is unable to respond to further
depolarisations until a sufﬁcient numbers of voltage-gated sodium
channels have returned to the resting state.13 AEDs with sodium
channel blocking properties have highest afﬁnity for the channel
protein in the inactivated state and binding slows the otherwise
rapid recycling process. As a result, these drugs produce a
characteristic voltage- and frequency-dependent reduction in
channel conductance, resulting in a limitation of repetitive
neuronal ﬁring with little effect on the generation of single action
potentials.14 While most sodium channel blocking AEDs interfere
with the fast inactivation pathway, lacosamide selectively
inﬂuences slow inactivation.15 Recent evidence suggests that this
drug can be usefully combined with sodium channel blockers that
act on fast inactivation.16
Voltage-gated calcium channels represent another important
target for several AEDs.17 The efﬁcacy of ethosuximide and
zonisamide in generalised absence epilepsy is believed to be
mediated by blockade of the low voltage-activated T-type calcium
channel in the dendrites of thalamocortical relay neurones.18,19Sodium valproate may have a similar action.20 Lamotrigine limits
neurotransmitter release by blocking both N- and P/Q-types of the
high-voltage-activated (HVA) calcium channel21 and levetirace-
tam exerts a partial blockade of N-type calcium currents.22
Phenobarbital, felbamate, and topiramate are also believed to
inﬂuence HVA calcium channel conductance, although their effects
are less well characterised in terms of channel subtypes or
interaction with speciﬁc protein subunits.8,9 Finally, gabapentin
and pregabalin also exert their effects via HVA calcium channels.
Uniquely, they bind to an accessory subunit, termed a2d-1, which
can modulate the function of various native channels.23
Activation of the ionotropic GABAA receptor resulting in an
enhanced response to synaptically released GABA is a major AED
mechanism.24 Phenobarbital and the benzodiazepines share this
effect. They bind to distinct sites on the receptor complex and
differentially inﬂuence the opening of the chloride ion pore.
Typical benzodiazepine-sensitive GABAA receptors are composed
of two a-subunits (a1, a2, a3 or a5), two b-subunits (b2 or b3),
and a g2 subunit, whereas barbiturates are less selective in terms
of subunit preference.25 Barbiturates prolong the duration of
chloride channel opening, while benzodiazepines increase the
frequency of opening.26 In addition, phenobarbital is capable of
direct activation of the GABAA receptor in the absence of GABA, an
effect which is believed to underlie its sedative properties.27
Stiripentol has been identiﬁed as a subunit selective GABAA
enhancer with a preference for a3-B3-g2 containing receptors.28
Felbamate and topiramate also modulate GABA responses at the
GABAA receptor. While their subunit speciﬁcity remains to be
established, their binding sites and effects on channel kinetics are
reported to be distinct from one another and from those observed
with barbiturates and benzodiazepines.29,30 Finally, levetiracetam
can indirectly inﬂuence GABAA receptor function by reducing the
negative allosteric modulation of the receptor complex by b-
carbolines and zinc.31
Vigabatrin and tiagabine exert their actions by selective
neurochemical effects at the inhibitory synapse, resulting in
altered GABA turnover.32 Vigabatrin is an irreversible inhibitor of
the mitochondrial enzyme GABA-transaminase, which is respon-
sible for the catabolism of GABA, whereas tiagabine prevents the
removal of GABA from the synaptic cleft by blockade of GABA
transport.33,34 These distinct mechanisms result in the global
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prolonged presence of neuronally released GABA in the synapse,
respectively. Although these drugs target neurones and glial cells,
vigabatrin has marginally higher afﬁnity for neuronal GABA-
transaminase, whereas tiagabine is slightly more effective in
reducing glial GABA uptake.32 Furthermore, tiagabine is selective
for the GAT-1 GABA transporter and its pharmacological effects
mirror the regional distribution of this protein with a more
pronounced action in hippocampus and neocortex.35 Other AEDs,
including sodium valproate, gabapentin and topiramate have also
been reported to inﬂuence GABA turnover by increasing neuro-
transmitter synthesis and/or release.36–38
None of the currently available AEDs exerts its effects solely by
an action on the glutamate system. Blockade of the NMDA subtype
of glutamate receptor is, however, believed to contribute to the
pharmacological proﬁle of felbamate.39 Topiramate is similarly
distinguished by an inhibitory action on AMPA and kainate
receptors with a higher afﬁnity for the latter.40 It has also been
suggested that zonisamide may inhibit glutamate-mediated
excitatory synaptic transmission, although this is likely to reﬂect
an indirect action on glutamate release mediated by pre-synpatic
blockade of sodium and calcium channels.41
Levetiracetamwas developed for the treatment of epilepsywith
no clear indication of how it worked at the cellular level. The
identiﬁcation of a speciﬁc binding site for the drug in mammalian
brain with its later classiﬁcation as synaptic vesicle protein 2A
(SV2A) has resulted in claims that levetiracetam represents the
ﬁrst in a new class of AEDs.42,43 However, the precise physiological
role of SV2A is still unclear and important details of the interaction
between drug and protein remain to be deﬁned. Indeed, there is
still no convincing evidence to suggest whether the interaction is
facilitatory or inhibitory or if it results in altered packaging,
trafﬁcking, membrane fusion or recycling of synaptic vesicles
within the nerve terminal.44 There is, however, credible evidence
to support selective binding of levetiracetam to SV2A with little or
no afﬁnity for other members of the same protein family, and an
impressive correlation between SV2A binding afﬁnity and the
anticonvulsant efﬁcacy of a series of levetiracetam analogues in
audiogenic seizure sensitive mice.42
The acid–base balance andmaintenance of local pH is critical to
normal functioning of the nervous system. Various isoenzymes of
carbonic anhydrase play an important role in this regard. They are
responsible for catalysing the bi-directional conversion of carbon
dioxide and water to bicarbonate and hydrogen ions
(CO2 + H2O$ HCO3 + H+). The forward reaction is rapid, whereas
the rate of the reverse reaction is more modest. As a result,
inhibition of carbonic anhydrase inﬂuences the latter more
signiﬁcantly, producing a localised acidosis and increased bicar-
bonate ion concentration.45 This, in turn, attenuates excitatory
neurotransmission by reducing NMDA receptor activity and
enhances inhibitory neurotransmission by facilitating the respon-
siveness of GABAA receptors.
46 Acetazolamide is a classical
carbonic anhydrase inhibitor which has been employed as an
AED for more than 50 years.47 Topiramate and zonisamide share
this mechanism, but are signiﬁcantly less potent and have greater
selectivity for individual isoenzymes. For instance, topiramate
selectively inhibits CA-II and CA-IV.48 Lacosamide may also inhibit
this enzyme.49 Thus, it is possible that inhibition of carbonic
anhydrase might make a modest contribution to the overall
efﬁcacy of a range of AEDs.
2.1. Experimental data
Animal models of seizures, epilepsy and drug-related neuro-
toxicity are widely used in the identiﬁcation of novel AEDs and
many of them have been in routine laboratory use for decades.50Together, these models offer an opportunity to characterise the
efﬁcacy and toxicity of individual drugs and drug combinations in
large groups of genetically homogeneous animals. Despite
question marks over their relevance to human epilepsy, and of
the doses and acute treatment regimens employed in preclinical
studies, these models have been instrumental in the identiﬁcation
of almost all current AEDs and, as such, are a valuable surrogate in
the search for optimal combination therapy.51 Those most
commonly used in anticonvulsant drug screening in rodents are
maximal electroshock (MES), pentylenetetrazol (PTZ) and spike-
wave and kindling models for efﬁcacy purposes and the rotarod,
horizontal screen, and chimney tests for neurotoxicity.52
Experimental combination studies should incorporate efﬁcacy
and toxicity models in which both drugs are at least minimally
effective, use drug ratios that reﬂect those employed clinically,
include drug concentration analysis in both plasma and brain to
rule out confounding pharmacokinetic interactions, and employ an
appropriate method of analysis such as isobolography or
comparison of protective indices.53 Isobolography is preferable
as it provides a robust measure of effectiveness and affords a
deﬁnitive determination of infra-additive (antagonistic), additive,
or supra-additive (synergistic) interactions.54 The ideal AED
combination displays pharmacological synergism, whether it is
deﬁned as improved efﬁcacy with similar toxicity, similar efﬁcacy
with improved toxicity or, ideally, improved efﬁcacy with
improved toxicity.
Experimental investigation of AED combinations has a long
pedigree.55 Early studies exploring combinations of established
drugs, such as phenobarbital, phenytoin, and carbamazepine, were
performed without any knowledge of their mechanisms of action.
Interestingly, combinations were commonly reported to be
superior, in terms of efﬁcacy, toxicity or both, than either
constituent drug alone irrespective of the drugs under investiga-
tion.56 However, this was most evident when two drugs with
differing mechanisms of action were combined, e.g. phenobarbital
with phenytoin.57 Less successful were combinations of AEDs with
similar mechanisms, e.g. phenytoin with carbamazepine.58 These
studies set the benchmark for the concept of rational polyphar-
macy as it evolved in the 1990s with the advent of modern AEDs,
which are invariably introduced as adjunctive therapy for
refractory partial epilepsy, and new knowledge surrounding
AED pharmacology.59
Identifying preferred combinations of AEDs, particularly when
starting a newdrug,might be regarded as advantageous in terms of
maximising efﬁcacy and minimising adverse effects. Considerable
experimental effort has been expended on studying combinations
of modern AEDs with their older counterparts and, more latterly,
with each other.60,61 Some common themes have emerged from
the vast literature, most notably that combining drugs with
differing mechanisms of action appears superior to combining
those possessing the same or similar cellular effects.56 This
observation is exempliﬁed by the consistent demonstration of
synergism between lamotrigine and sodium valproate in multiple
efﬁcacy models62,63 and the repeated failure to demonstrate
synergism between lamotrigine and either carbamazepine or
phenytoin.62,64 Other combinations appear to produce less
consistent results; for example, gabapentin with carbamazepine
is synergistic in the MES model but not in the DBA/2 audiogenic-
seizure susceptible mouse.65,66 Overall, the message is relatively
clear; reinforcement on a single pharmacological pathway is less
effective than a combined effect on two distinct pathways.
Themost successful two drug combination in laboratory studies
appears to be a single mechanism drug combined with an AED
known to possess multiple mechanisms of action.56 Combinations
of drugs that selectively target neuronal voltage-gated sodium
channels appear to offer only additive improvements in efﬁcacy
[()TD$FIG]
Fig. 2.Median monthly seizure counts for patients receiving add-on lamotrigine to
baseline treatment with phenytoin, carbamazepine or sodium valproate. The study
consisted of a 12-week ‘‘baseline phase’’ of the original baseline monotherapy,
followed by the ‘‘add on phase’’ when lamotrigine was introduced with baseline
medication unchanged. Patients showing at least 50% reduction in seizure
frequency compared with baseline entered the 12-week ‘‘withdrawal phase’’
when the baseline antiepileptic drug was tapered off. Patients who successfully
completed the withdrawal phase entered the lamotrigine ‘‘monotherapy phase’’ of
12 weeks duration.(reproduced from Ref. [71], with permission).
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tunately, there are no meta-analyses or systematic reviews of
experimental combination studies which would permit an
objective assessment of the available data. This is most likely
due to variability in experimental methodology and the difﬁculty
in comparing results across multiple studies. Many investigations
are also incomplete; neurotoxicity testing is often not reported,
which undermines any suggestion of synergism in terms of
efﬁcacy. Pharmacokinetic analysis is rarely performed, which is
necessary to rule out the potential for altered drug absorption or
brain penetration.
2.2. Clinical evidence
The situation regarding clinical evidence in support of ‘‘rational
polytherapy’’ is similarly sparse.67–69 There are claims in the
literature supporting particular efﬁcacy for combinations including
a sodium channel blocker with a GABA-ergic drug56 or one with
multiple mechanisms of action.70 However, once again the only
supportive evidence for synergism is with sodium valproate and
lamotrigine. Brodie and colleagues undertook a pragmatic trial
during which an attempt was made to substitute lamotrigine as
monotherapy in patients suboptimally treatedwith carbamazepine,
phenytoin or sodium valproate.71 Adjustment was made in the
lamotrigine dosing schedules for the pharmacokinetic interactions
among these drugs resulting in similar circulating lamotrigine
concentrations for all 3 combinations. When patients were
established on both drugs, it was noted that the efﬁcacy was
substantially higher in the valproate group than in the patients
taking lamotrigine with carbamazepine or phenytoin (Fig. 2).
Following up on this observation, Pisani et al. performed a well-
designed crossover study in 20 patients with partial seizures
stabilised on combination therapy.72 Among the 13 who did not
respond to the consecutive addition of sodium valproate and
lamotrigine, fourpatients becameseizure freeandanadditional four
experienced>50% seizure reductionwhen both drugswere given in
combination despite lower doses and circulating concentrations
than occurred during their separate administration.
Other useful combinations suggested in the literature are
largely based on anecdotal reports in small groups of patients or
studies with modest sample sizes. These include valproate with
ethosuximide for absence seizures,73 phenobarbital with phenyt-
oin for generalised tonic–clonic seizures,74 carbamazepine with
valproate or vigabatrin for partial seizures,75 vigabatrin with
tiagabine for partial seizures76 and lamotriginewith topiramate for
a range of seizure types.77
Interestingly, in a multicentre double-blind, placebo-con-
trolled, randomized, parallel group trial of ruﬁnamide 1600 mg
twice daily in adults and adolescents with refractory partial
seizures, there was a 12% reduction in monthly seizure frequency
in the 96 patients established on carbamazepine compared with a
29% seizure reduction (p = 0.05) in the 60 patients taking a regimen
that did not contain carbamazepine.78 Arguably, this observation
could suggest that carbamazepine and ruﬁnamide have similar
effects on voltage-dependent sodium channels. More recently it
has been demonstrated in placebo-controlled dose ranging
adjunctive trials with lacosamide that response to this drug was
less impressive in patients established on traditional sodium
blockers than those taking AEDs with different mechanisms of
action, although a dose-dependent statistically signiﬁcant im-
provement over placebo was demonstrated in both groups.16
Combining drugs that block voltage-dependent sodium chan-
nels is more likely to produce neurotoxic side-effects, such as
dizziness, diplopia and ataxia.71,79–81 A similar scenario, particu-
larly related to a greater likelihood of dizziness, has been reported
in patients established on traditional sodium channel blockerscompared with those taking other AEDs in a pooled analysis of
clinical trial data with adjunctive lacosamide.16 Introducing
lamotrigine in patients established on sodium valproate produces
a substantially greater risk of allergic rash than occurs in patients
starting on the drug as monotherapy.82 This is presumed to be a
consequence of the inhibitory effect of valproate on lamotrigine
metabolism resulting in higher concentrations.
2.3. Improved outcomes
There is increasing evidence that the prognosis of treated
epilepsy has improved over the past decade, although this has not
had a major impact in substantially reducing the size of the
refractory epilepsy population.83–85 This is perhaps not too
surprising since the placebo-corrected efﬁcacy of adjunctive
treatment with modern AEDs in double-blind randomized trials
has been disappointingly small86 with very few patients becoming
seizure-free even for the limited duration of the study.87
Data from the expanding cohort of adolescents and adults with
newly diagnosed epilepsy in Glasgow, Scotland also support the
suggestion that the prognosis has marginally improved since the
ﬁrst analysis a decade ago reported a likely bleak outcome
following failure of the ﬁrst drug due to lack of efﬁcacy.88 With the
advent of a range of mechanistically different AEDs, some patients
will now respond to their 3rd, 4th or 5th treatment schedules.89
Overall a higher percentage of this expanding population had
attained seizure-freedom by 2008 (n = 1098; 68.4%) than in the
initial analysis conducted in 1998 (n = 470; 64%). Of the 70 in this
cohort controlled on polypharmacy, 67 (96%) were taking just two
AEDs. These data support those of Schiller and Najjar in suggesting
that patients need to fail ﬁve, six or even seven drug schedules
before they can be recognised as having truly refractory epilepsy.85
This picture appears similar for the common childhood epilep-
sies.90,91
2.4. Drug usage
The mechanisms of action of the currently marketed drugs are
relatively limited since their anti-seizure properties were identi-
ﬁed using a similar array of rodent seizure models.92 They all
inhibit the onset and/or spread of abnormal neuronal synchrony
either by decreasing excitation and/or increasing inhibition.8
Given that we know little about the processes in the brain of
individual patients that trigger the initiation of a seizure or switch
off the abnormal electrical activity, it seems reasonable to combine
AEDs that are pharmacologically distinct.93. Even thoughwe do not
Table 2
Guidance for combining antiepileptic drugs.
Establish optimal dose of baseline agent
Add drug with multiple mechanisms
Avoid combining similar modes of action
Titrate new agent slowly and carefully
Be prepared to reduce dose of original drug
Replace less effective drug if response still poor
Try range of different duotherapies
Add third drug if still sub-optimal control
Devise palliative strategy for refractory epilepsy
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drugs, we can make a good start at separating those that work in
similar ways from those that act differently. These are simpliﬁed
and summarised in Table 1. This forms the template for those AEDs
that can reasonably be combined in patients with drug-resistant
epilepsy.
AEDs have different spectra of activity with most sodium
blockers, except ruﬁnamide and possibly also lamotrigine, having
efﬁcacy for partial and tonic–clonic seizures only. It has been
suggested for some time that better outcomes can be obtained in
patients established on a sodium channel blocker in combination
with a drug that possess a different mechanism of action.94
Regulatory trial data have demonstrated that lacosamide can be
usefully combined with traditional sodium blocking agents.16
Ethosuximide use is largely conﬁned to absence seizures, whereas
gabapentin and pregabalin are used for partial seizures with or
without secondary generalisation.95 As we do not understand how
seizures are generated and propagated in the brains of individual
patients, adding molecules that possess multiple mechanisms of
action, such as valproic acid, levetiracetam, topiramate and
zonisamide, may be more likely to provide a beneﬁcial pharmaco-
logical effect in the setting of refractory epilepsy.56,70 These agents
also tend to be broad spectrum across a range of seizure types.
Interestingly, the barbiturates and benzodiazepines, which act on
the GABAA receptor, also have a broader range of efﬁcacy than
other GABA-ergic drugs, such as vigabatrin and tiagabine, that have
a selective effect on GABA turnover. In addition there are a handful
of AEDs in the pipeline with novel mechanisms of action that
should offer opportunities for new and pharmacologically distinct
combinations.96 In particular ezogabine/retigabine (potassium
channel opener) and perampanel (selective (AMPA/kainate antag-
onist) may be useful additions to the therapeutic armamentarium
for drug-resistant epilepsy.
If a patient tolerates the ﬁrst, second or third monotherapywell
with a useful but suboptimal response, combination therapy
should be considered, particularly if there is a high seizure density
and demonstrable underlying pathology, such as mesial temporal
sclerosis or cortical dysplasia (Table 2). Several duotherapy
combinations should be tested sequentially before adding a third
drug. Higher numbers of AEDs should be avoided if possible as it is
highly unlikely that this strategy will produce useful seizure
reduction without side effects.97
A personalized treatment plan should be formulated once a
patient fulﬁls the criterion for drug-resistant epilepsy to limit as far
as possible cognitive deterioration and psychosocial dysfunction,
while taking into consideration seizure type(s) and syndromeTable 1
Different mechanistic groups suitable for combination therapy.
1Sodium channel blockers
(a) Fast-inactivated state—phenytoin, carbamazepine, lamotrigine, oxcarbaze-
pine, eslicarbazepine
(b) Slow-inactivated state—lacosamide
2Calcium channel blockers
(a) Low voltage activated channel—ethosuximide
(b) High voltage activated channel—gabapentin, pregabalin
3GABA-ergic drugs
(a) Prolongs chloride channel opening—barbiturates
(b) Increased frequency of chloride channel opening—benzodiazepines
(c) Inhibits GABA-transaminase—vigabatrin
(d) Blocks synaptic GABA reuptake—tiagabine
4Synaptic vesicle protein 2A modulation—levetiracetam
5Carbonic anhydrase inhibition—acetazolamide
6Multiple pharmacological targets—sodium valproate, felbamate, topiramate,
zonisamide, ruﬁnamideclassiﬁcation.98 This has recently been deﬁned by an International
League Against Epilepsy task force as ‘‘failure of an adequate trial of
two tolerated, appropriately chosen and used AED schedules
(whether as monotherapies or in combination) to achieve
sustained seizure freedom’’.99 The development of this deﬁnition
encourages a more aggressive approach toward earlier combina-
tion therapy and more rapid access to non-pharmacological
treatment options, such as vagal nerve stimulation or epilepsy
surgery.100 Special attention should be paid to drug load to avoid
side-effects and optimise the potential for complete seizure
control.101 It would also be worthwhile raising the possibility at
this early stage that seizure freedommay not be attainable, paving
the way for a later palliative strategy if this proves to be necessary.
All patients with refractory epilepsy should be informed of the risk
of sudden unexpected death in epilepsy and appropriate precau-
tions taken.102
Even with the contribution from experimental combination
studies, the issue of rational polypharmacy for epilepsy remains
largely unresolved. This is, to some extent, due to uncertainty
about the deﬁnition. If it is the application of common sense, then
we should combine drugs with different, perhaps multiple,
mechanisms of action in order to cover more pharmacological
bases. If it is to be evidence-based, then robust evidence does not
exist in support of the above strategy with the exception of
combining sodium valproate with lamotrigine. Whatever strategy
we use is confounded by our incomplete understanding of how
AEDs work, not to mention our lack of knowledge about the
neurobiologies underpinning most epilepsies. These deﬁciencies
arguably limit our ability to use single drugs in a rational manner,
far less in combinations. However, on the basis of current
experimental and clinical evidence, it would appear that combin-
ing AEDs with similar mechanisms of action is counter-intuitive
and counter-productive. At present, however, this principle can
only be reasonably applied to selective sodium channel blockers
and not other mechanistic classes of AEDs.
3. Conclusion
After being viewed as a last resort for many years, the role of
combination therapy as an acceptable treatment strategy for
epilepsy is undergoing re-evaluation. This is a result of the growing
appreciation that a substantial proportion of patients will not
respond optimally to monotherapy, coupled with the availability
of awide range ofmodern AEDs, some ofwhich are better tolerated
and less prone to complex pharmacokinetic drug interactions than
their older counterparts. Convincing evidence to guide clinicians
on when and how to combine AEDs is still lacking, and current
practice recommendations remain empirical. Well designed
studies exploring the ever expanding possibilities of AED
combinations would address these practical questions so that
effective therapy could be offered to many more patients in a
pharmacologically targeted fashion. Amechanistic approach to the
pharmacological management of each epilepsy syndrome has the
potential to optimise the chance of perfect seizure control and help
more people achieve safer and more fulﬁlled lives. A palliative
M.J. Brodie, G.J. Sills / Seizure 20 (2011) 369–375374strategy will be necessary for the many patients with truly
refractory epilepsy.
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